Monster Beverage: Drink it Up?

Takeaway: Monster is changing how it classifies one of its products. That doesn't change our opinion on the stock.

Monster Beverage Corp (MNST) announced Wednesday they will market their caffeine-laced product as a “beverage,” not as a “dietary supplement.”  This does nothing to alter our bearish take on the company.  Additionally, our estimates for first-half earnings remain below Street consensus.   


Dietary supplements are regulated by the FDA.  But so are foods? you ask, and you are right.  Because of the way the FDA categories are drawn, makers of energy drinks have flexibility to define their products as either “supplement” or “food.”  One perceived benefit of being a Food is that makers of Supplements are required to report adverse consequences of product use to the Agency.  Such notification is purely voluntary for makers of Foods.


Health Concerns


But MNST can’t get itself out of the crosshairs just by changing category.  The national Drug Abuse Warning Network (DAWN) gathers hospital statistics on adverse reactions to substances, regardless of FDA classification.  DAWN statistics around caffeine-based products – not to mention lawsuits against the manufacturers – present an ongoing image problem for MNST.  The decision to become a Food doesn’t address this.


What Can MNST Do?


We would like to see MNST get out in front of regulatory developments by taking two steps: disclosing caffeine content, and staying away from advertising that is targeted at consumers under 18 years old.  We believe both of these are likely to be mandated soon, and voluntary action now could give MNST a leading voice in the debate surrounding this segment.




We don’t like MNST any better than before this announcement, and we’re not convinced this move raises their profile.  If the company follows up by putting itself at the head of the debate, they will have accomplished something concrete – though perhaps still not enough for us to turn bullish, given our dim view of near-term earnings.




GOLD: A Deep Dive on What’s Next with a Top Commodities Strategist

“If you saved in gold over the past 20 to 25 years rather than any currency anywhere in the world, gold has outperformed all these currencies,” says Stefan Wieler, Vice President of Goldmoney in this edition of Real Conversations.

read more

Exact Sciences Up +24% This Week... What's Next? | $EXAS

We remain long Exact Sciences in the Hedgeye Healthcare Position Monitor.

read more

Inside the Atlanta Fed's Flawed GDP Tracker

"The Atlanta Fed’s GDPNowcast model, while useful at amalgamating investor consensus on one singular GDP estimate for any given quarter, is certainly not the end-all-be-all of forecasting U.S. GDP," writes Hedgeye Senior Macro analyst Darius Dale.

read more

Cartoon of the Day: Acrophobia

"Most people who are making a ton of money right now are focused on growth companies seeing accelerations," Hedgeye CEO Keith McCullough wrote in today's Early Look. "That’s what happens in Quad 1."

read more

People's Bank of China Spins China’s Bad-Loan Data

PBoC Deputy Governor Yi says China's non-performing loan problem has “pretty much stabilized." "Yi is spinning. China’s bad-debt problem remains serious," write Benn Steil and Emma Smith, Council on Foreign Relations.

read more

UnderArmour: 'I Am Much More Bearish Than I Was 3 Hours Ago'

“The consumer has a short memory.” Yes, Plank actually said this," writes Hedgeye Retail analyst Brian McGough. "Last time I heard such arrogance was Ron Johnson."

read more

Buffalo Wild Wings: Complacency & Lack of Leadership (by Howard Penney)

"Buffalo Wild Wings has been plagued by complacency and a continued lack of adequate leadership," writes Hedgeye Restaurants analyst Howard Penney.

read more

Todd Jordan on Las Vegas Sands Earnings

"The quarter actually beat lowered expectations. Overall, the mass segment performed well although base mass lagging is a concern," writes Hedgeye Gaming, Lodging & Leisure analyst Todd Jordan on Las Vegas Sands.

read more

An Update on Defense Spending by Lt. Gen Emo Gardner

"Congress' FY17 omnibus appropriation will fully fund the Pentagon's original budget request plus $15B of its $30B supplemental request," writes Hedgeye Potomac Defense Policy analyst Lt. Gen Emerson "Emo" Gardner USMC Ret.

read more

Got Process? Zero Hedge Sells Fear, Not Truth

Fear sells. Always has. Look no further than Zero Hedge.

read more

REPLAY: Review of $EXAS Earnings Call (A Hedgeye Best Idea Long)

Our Healthcare Team made a monster call to be long EXAS - hear their updated thoughts.

read more

Capital Brief: 5 Things to Watch Right Now In Washington

Here's a quick look at some key issues investors should keep an eye on from Hedgeye's JT Taylor and our team of Washington Policy analysts in D.C.

read more